Metatensin #4
Drug - Metatensin #4
The trade name of the product as shown on the labeling.
Dosage -
TABLET; ORAL
The product dosage form and route separated by a semi-colon.
Active Ingredient(s) -
Reserpine; Trichlormethiazide
Multiple ingredients are in alphabetical order.
Strength -
0.1MG;4MG
The potency of the active ingredient(s), Reserpine; Trichlormethiazide. May repeat for multiple part products.
Applicant -
AVENTIS PHARMS
The firm name holding legal responsibility for Metatensin #4. The firm name is condensed to a maximum twenty character unique string.
New Drug Application (NDA) Number -
012972
The FDA assigned number to Metatensin #4. Format is nnnnnn.
Product Number -
002
The FDA assigned number to identify Metatensin #4. Each strength is a separate product. May repeat for multiple part products. Format is nnn.
Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.
Approval Date -
Approved Prior to Jan 1, 1982
The date Metatensin #4 was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".
Reference Listed Drug (RLD) -
No
The pioneer or innovator of Metatensin #4. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.
Type -
DISCN
The group or category of approved drugs Metatensin #4 is in. Format is RX, OTC, DISCN.
Applicant Full Name -
Aventis Pharmaceuticals Inc
The full name of the firm holding legal responsibility for the new application of Metatensin #4.
Metatensin #4
|